Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	1818885-28-7
Formula :	C₄₆H₄₇ClN₈O₉S
M.W :	923.43
SMILES Code :	CC1=NN=C2N1C(SC(C)=C3C)=C3C(C4=CC=C(Cl)C=C4)=N[C@H]2CC(NC5=CC=C(OCCOCCOCCOCCNC6=C(C(N(C7CCC(NC7=O)=O)C8=O)=O)C8=CC=C6)C=C5)=O
MDL No. :	MFCD29472237
InChI Key :	RWLOGRLTDKDANT-TYIYNAFKSA-N
Pubchem ID :	92044400

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

MDA-MB-231	0.4 µM	12, 24, or 48 hours	ARV-825 significantly reduced the expression levels of BET proteins BRD4 and BRD2, although the reduction of BRD4 was milder in the resistant cells.	J Exp Clin Cancer Res. 2019 Aug 30;38(1):383.
MDA-MB-231R	0.4 µM	12, 24, or 48 hours	ARV-825 significantly reduced the expression levels of BET proteins BRD4 and BRD2, although the reduction of BRD4 was milder in the resistant cells.	J Exp Clin Cancer Res. 2019 Aug 30;38(1):383.
MDA-MB-231	0.5 µM	24 hours	ARV-825 inhibits mammosphere formation in MDA-MB-231 cells and reduces CD44+/CD24- and ALDH expressing subpopulations.	Cell Commun Signal. 2023 Nov 3;21(1):315.
HCC1937	0.1 µM	24 hours	ARV-825 inhibits mammosphere formation in HCC1937 cells and reduces ALDH expressing subpopulations.	Cell Commun Signal. 2023 Nov 3;21(1):315.
SKO-007(J3)	0.2 µM	24 hours	ARV-825 significantly downregulated IRF4 and cMYC expression and upregulated MICA expression.	J Hematol Oncol. 2016 Dec 1;9(1):134.
LPS141	200 nM	24 hours	To evaluate the anti-proliferative effect of ARV-825 on LPS141 cells, results showed that ARV-825 significantly inhibited cell proliferation.	Nat Commun. 2019 Mar 22;10(1):1353.
MLS402	200 nM	24 hours	To evaluate the anti-proliferative effect of ARV-825 on MLS402 cells, results showed that ARV-825 significantly inhibited cell proliferation.	Nat Commun. 2019 Mar 22;10(1):1353.
SUP-T1 cells	20 nM	24 hours	ARV-825 treatment resulted in downregulation of MYC and CD44 expression, along with decreased protein levels of NOTCH1, MYC, and CD44.	Leukemia. 2022 May;36(5):1261-1273.
KOPT-K1 cells	50 nM	24 hours	ARV-825 treatment led to significant downregulation of CD44 and CD44v8-10 mRNA and increased intracellular ROS levels.	Leukemia. 2022 May;36(5):1261-1273.
SET2 cells	1.0 µM	24 hours	To compare the effects of ARV-825 and OTX015 on the levels of BRD4 and BRD2 in sAML SET2 cells, the results showed that ARV-825 significantly reduced the levels of BRD4 and BRD2.	Leukemia. 2017 Sep;31(9):1951-1961.
GL261 cells	0.0625 μg/ml	24 hours	To evaluate the cytotoxicity of cRGD-P/ARV-DOX on GL261 cells, the results showed that cRGD-P/ARV-DOX had greater cytotoxicity to GL261 cells at 24 h and 48 h.	Mater Today Bio. 2022 Sep 12;16:100423.
B16 cells	200 ng/mL	24 hours	ARV-825 significantly reduced the viability of B16 cells, and MNC@Ca/MnCO3/ARV nanoparticles showed stronger cytotoxicity, significantly inducing ferroptosis in B16 cells.	Mater Today Bio. 2025 Jan 24;31:101523.
DC2.4 cells	200 ng/mL	24 hours	ARV-825 showed no significant toxicity to DC2.4 cells, indicating its safety for normal immune cells.	Mater Today Bio. 2025 Jan 24;31:101523.
SKO-007(J3)	0.2 µM	48 hours	ARV-825 significantly inhibited IRF4 and cMYC mRNA expression and upregulated MICA mRNA expression.	J Hematol Oncol. 2016 Dec 1;9(1):134.
GL261 cells	100 ng/mL	48 hours	To evaluate the effects of ARV-825 on cell proliferation, cell cycle, and apoptosis, results showed that ARV-825 significantly inhibited cell proliferation, induced apoptosis, and blocked the cell cycle.	Adv Sci (Weinh). 2024 Dec;11(48):e2409753.
LN229 cells	100 ng/mL	48 hours	To evaluate the effects of ARV-825 on cell proliferation, cell cycle, and apoptosis, results showed that ARV-825 significantly inhibited cell proliferation, induced apoptosis, and blocked the cell cycle.	Adv Sci (Weinh). 2024 Dec;11(48):e2409753.
U251 cells	100 ng/mL	48 hours	To evaluate the effects of ARV-825 on cell proliferation, cell cycle, and apoptosis, results showed that ARV-825 significantly inhibited cell proliferation, induced apoptosis, and blocked the cell cycle.	Adv Sci (Weinh). 2024 Dec;11(48):e2409753.
U87 cells	100 ng/mL	48 hours	To evaluate the effects of ARV-825 on cell proliferation, cell cycle, and apoptosis, results showed that ARV-825 significantly inhibited cell proliferation, induced apoptosis, and blocked the cell cycle.	Adv Sci (Weinh). 2024 Dec;11(48):e2409753.
UKE1 cells	256 ± 12.45 nM	48 hours	To compare the effects of ARV-825 and OTX015 on apoptosis in UKE1 cells, the results showed that ARV-825 induced significant apoptosis at a concentration of 256 ± 12.45 nM.	Leukemia. 2017 Sep;31(9):1951-1961.
U251 cells	0.125 μg/ml	48 hours	To evaluate the cytotoxicity of cRGD-P/ARV-DOX on U251 cells, the results showed that cRGD-P/ARV-DOX had better synergetic anti-cancer effects at 48 h.	Mater Today Bio. 2022 Sep 12;16:100423.
BT549	0.2, 0.4, and 1 µM	48 or 96 hours	ARV-825 exhibited significant antiproliferative activity in BT549 cells.	J Exp Clin Cancer Res. 2019 Aug 30;38(1):383.
SKOV3	0.2, 0.4, and 1 µM	48 or 96 hours	ARV-825 exhibited significant antiproliferative activity in SKOV3 cells.	J Exp Clin Cancer Res. 2019 Aug 30;38(1):383.
OVCAR3	0.2, 0.4, and 1 µM	48 or 96 hours	ARV-825 exhibited significant antiproliferative activity in OVCAR3 cells.	J Exp Clin Cancer Res. 2019 Aug 30;38(1):383.
Jurkat	1 µM	7 days	ARV-825 significantly inhibited the proliferation of Jurkat cells and suppressed cell growth by inducing cell cycle arrest and apoptosis.	Cancer Cell Int. 2021 Apr 22;21(1):230.
CCRF-CEM	1 µM	7 days	ARV-825 significantly inhibited the proliferation of CCRF-CEM cells and suppressed cell growth by inducing cell cycle arrest and apoptosis.	Cancer Cell Int. 2021 Apr 22;21(1):230.
Molt4	1 µM	7 days	ARV-825 significantly inhibited the proliferation of Molt4 cells and suppressed cell growth by inducing cell cycle arrest and apoptosis.	Cancer Cell Int. 2021 Apr 22;21(1):230.
6 T-CEM	1 µM	7 days	ARV-825 significantly inhibited the proliferation of 6 T-CEM cells and suppressed cell growth by inducing cell cycle arrest and apoptosis.	Cancer Cell Int. 2021 Apr 22;21(1):230.

Mice	GL261 subcutaneous tumor model	Intravenously injected	10 mg/kg	Every two days for a total of four times	To evaluate the antitumor efficacy of ARV-825 in vivo, results showed that ARV-825 significantly inhibited tumor growth and prolonged the survival of mice.	Adv Sci (Weinh). 2024 Dec;11(48):e2409753.
Nude mice	T-ALL xenograft model	Intraperitoneal injection	10 mg/kg	Once daily for 14 days	ARV-825 significantly inhibited tumor growth in the T-ALL xenograft model and suppressed tumor proliferation by downregulating BRD4 and c-Myc protein expression.	Cancer Cell Int. 2021 Apr 22;21(1):230.
C57BL/6 mice	Melanoma model	IntratumOral injection	100 μL	Injected on days 7, 11, and 15, continued until day 22	MNC@Ca/MnCO3/ARV/anti-PD1 nanoparticles significantly inhibited melanoma growth and enhanced anti-tumor immune responses, successfully constructing an in situ tumor vaccine.	Mater Today Bio. 2025 Jan 24;31:101523.
C57BL/6 mice	Subcutaneous glioma model	Intravenous injection	2.5 mg/kg	Every three days for three consecutive times	To evaluate the anti-tumor efficacy of cRGD-P/ARV-DOX in the subcutaneous glioma model, the results showed that cRGD-P/ARV-DOX significantly inhibited tumor growth.	Mater Today Bio. 2022 Sep 12;16:100423.
Balb/c Nude mice	TNBC tumor model	Intravenous injection	3.5 mg/kg	Every other day for a total of 5 times	To evaluate the antitumor effect of ARV-MBs combined with ultrasound in the TNBC tumor model, the results showed that ARV-MBs combined with ultrasound significantly inhibited tumor growth, with a tumor inhibition rate of 81.4%.	Biomater Res. 2024 Aug 13;28:0064
NSG mice	LPS141 xenograft model	Intraperitoneal injection	5 mg/kg	Once daily, 5 days per week, continuous treatment	To evaluate the anti-tumor effect of ARV-825 on the LPS141 xenograft model, results showed that ARV-825 significantly delayed tumor growth and prolonged mouse survival.	Nat Commun. 2019 Mar 22;10(1):1353.
Mice	T-ALL PDX model	Intraperitoneal injection	5 mg/kg or 10 mg/kg	Three times a week for several weeks	ARV-825 treatment significantly reduced leukemia burden and prolonged the survival of mice.	Leukemia. 2022 May;36(5):1261-1273.

{[proInfo.proName]}

CAS No.: 1818885-28-7

{[proInfo.proName]}

CAS No.: 1818885-28-7

Alternative Products

Product Details of ARV-825

Safety of ARV-825

Related Pathways of ARV-825

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	1.08mL 0.22mL 0.11mL	5.41mL 1.08mL 0.54mL	10.83mL 2.17mL 1.08mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed